Identification of benzothiazoles as novel PCSK9 inhibitors.
Bioorg Med Chem Lett
; 97: 129542, 2024 01 01.
Article
em En
| MEDLINE
| ID: mdl-37939861
ABSTRACT
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a clinically validated target on the treatment of cardiovascular disease (CVD). PCSK9 can regulate the hepatocyte surface low density lipoprotein receptor (LDLR) level by binding to LDLR and leading to their degradation in the lysosome. The clinical use of two monoclonal antibodies (alirocumab and evolocumab, approved in 2015) and one small interfering RNA (inclisiran, approved in 2020) which can inhibit PCSK9 function proved that they are very effective in lowering low density lipoprotein cholesterol (LDL-C). However, the high treatment costs and parenteral administration of these drugs prohibited widespread use and reduced their long-term advantage. Comparatively, small molecule drugs have many incomparable advantages of macromolecules, such as lower treatment cost, more drug administration options, superior pharmacokinetic properties, less adverse immunogenic responses and better affordable production. In this paper, we identified a series of benzothiazoles small molecule PCSK9 inhibitors through extensive screening. The structure and activity relationship (SAR) was summarized to facilitate further optimization. Moreover, the primary mechanism of action of the most potent compound was also investigated.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Benzotiazóis
/
Inibidores de PCSK9
/
Anticolesterolemiantes
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article